Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock price
Is Cardiol Therapeutics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock Analysis
Analyst Opinions
8 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:
Analyst Opinions
8 Analysts have issued a Cardiol Therapeutics Inc - Ordinary Shares - Class A forecast:
Don't miss a Thing! We will send you all news about Cardiol Therapeutics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cardiol Therapeutics Inc - Ordinary Shares - Class A Stock News
Company Profile
Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its product, CardiolRx, is a pharmaceutically produced extra strength oral cannabidiol formulation that is entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
| Head office | Canada |
| CEO | Mr. Elsley |
| Employees | 18 |
| Founded | 2017 |
| Website | www.cardiolrx.com |


